Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for March 2009
March 2, 2009
- Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
- Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
- Astellas and XenoPort Announce Positive Results from Phase 2 Trial of ASP8825/XP13512 in Japan for Restless Legs Syndrome
- Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
- Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba
- NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009
- Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory and Anti-Fungal Candidates, AN2728, AN2898 and AN2718, at the American Academy of Dermatology Annual Meeting
- New head-to-head data published in The Lancet: Prasugrel reduces cardiovascular event risk in high-risk heart attack patients when compared to clopidogrel
March 3, 2009
- Drug Resistant Influenza A Virus Potentially Serious to High-Risk Patients
- Inactivated Flu Vaccine Associated With Fewer Medical Visits for Respiratory Illness Than Intranasal Vaccine
- Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
- Rituximab Reduces Kidney Inflammation in Patients with Lupus
March 4, 2009
- EPIX Pharmaceuticals to Present Alzheimer's Disease Data at the American Society for Experimental NeuroTherapeutics Annual Meeting
- Anacor Announces Positive Results From Phase 1 Trial of AN2718
March 5, 2009
- Opexa Provides Key Quality of Life Data on Tovaxin for Multiple Sclerosis
- Access Pharmaceuticals Announces Positive ProLindac Phase 2 Ovarian Cancer Clinical Trial Results
- Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
- Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
- CV Therapeutics Reports Phase 1 Data Showing Proof of Concept for CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
- Cypher Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Six-Year Randomized Clinical Trial
- The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
March 6, 2009
- Anacor Announces Positive Results from Phase 1 Safety Trial of AN2898 for Psoriasis and Atopic Dermatitis
- Basilea Pharmaceutica Ltd. (CH) - Basilea presents research data on a novel antibiotic at the Anti-Infectives Partnering & Deal-Making Summit
- Sepracor Reports Preliminary Phase II Study Results for SEP-225441 for the Treatment of Generalized Anxiety Disorder
- Peplin's Positive Phase IIb AK Trial Result Details
- Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex Spray Followed by Vectical Ointment in Managing Plaque Psoriasis
March 9, 2009
- Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon in Chronic Hepatitis C
- AndroScience Corporation Announces Phase 2a Study Results on ASC-J9 for the Treatment of Acne
- Human Genome Sciences to Sponsor Conference Call - Mar 9, 2009
March 10, 2009
- ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009
- Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
- Bayhill Therapeutics to Present Phase II Follow-up Data on BHT-3009 for Treatment of Multiple Sclerosis
- Biothera to Release Cancer Data at 2009 ASCO Meeting
- Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
- Generex Biotechnology Announces Successful Phase III Study Data for Generex Oral-lyn
- New Insights into the Mechanism of Action of Antipsychotic Drugs
March 11, 2009
- Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
- GW Reports Positive Outcome of Sativex Phase III Multiple Scelerosis Study
- Clinical Data, Inc. Announces Publication of Results from First Phase III Study of Vilazodone in Treatment of Major Depressive Disorder
- Two Publications Highlight Vilazodone as Strong Potential Treatment for Depression
March 12, 2009
- Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
- Researchers Investigate Rituximab Potential
- Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
- QLT Announces Completion of Phase Ia Safety Trial of its Synthetic Retinoid Product
- Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
- pSivida Corp Reports Favorable 12-Month Interim Safety and Efficacy Results from Iluvien Human PK Study
March 13, 2009
- Arimidex offers women greater protection against HR+ early breast cancer returning in the 1st 2 yrs
- The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
- Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
- YM BioSciences Announces Nimotuzumab Presentations to be Made at the 100th Annual Meeting of the American Association for Cancer Research and European Society for Medical Oncology
March 16, 2009
- Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347
- Oncolytics Biotech Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
- Clavis Pharma ASA (NO) - Clavis Pharma Announces Positive Elacytarabine Phase II Results
- New, Published Gelnique Data Show Efficacy, Convenience and Excellent Tolerability
- C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute Swelling Attacks Across All Body Sites in Patients with Hereditary Angioedema, According to Study
- Avexa Reports Positive 96 Week Data for HIV Drug Apricitabine (ATC)
- CyDex Pharmaceuticals Presents Phase 2 Clinical Trial Results for Captisol-Enabled Budesonide/Azelastine Combination Solution Nasal Spray at American Academy of Allergy Asthma and Immunology (AAAAI) Meeting
- CytRx's Arimoclomol Demonstrates Statistically Significant Neurorestorative Results in a Preclinical Embolic Stroke Trial
- DURECT Reports Positive Phase IIb Data from TRANSDUR-Sufentanil Clinical Program
- Adult Stem Cell Study Demonstrates Improved Quality of Life for Patients Suffering from Spinal Cord Injury
- New, published data demonstrate effectiveness/excellent tolerability for first topical OAB treatment
- Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
- Unigene Reports Positive PTH Clinical Study Results
- Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient
March 17, 2009
- Cytheris Announces Publication of IL-7 HIV Data in The Journal of Clinical Investigation
- Cephalon Announces Positive Results From a Phase Two Study of Nuvigil in Bipolar Depression
- Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
- Study Demonstrates That QVAR is More Likely to Achieve Successful Asthma Control with Less Exacerbations
March 18, 2009
- BEMA Buprenorphine to Proceed to Phase 2 Following Favorable Initial Study Results
- EPIX Pharmaceuticals to Present Preclinical Data at the 237th American Chemical Society National Meeting and Exposition
- ULURU Inc. to Present Altrazeal Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
- Medication Does Not Appear to Reduce Progression of Atherosclerosis
- Narcolepsy Drug Being Used to Improve Cognitive Performance Affects Brain Dopamine Activity, Suggesting Potential For Abuse and Dependence
March 19, 2009
- SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
- Cytochroma announces new findings regarding the role of CYP24 in chronic kidney disease
- Glivec Substantially Reduces Risk Of Cancer Returning In Patients With Life-Threatening Gastrointestinal Stromal Tumors, The Lancet Reports
- Gleevec Substantially Reduces Risk of Cancer Returning in Patients with Life-threatening Gastrointestinal Stromal Tumors (GIST), The Lancet Reports
- Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
- AngioChem's ANG1005 Shows Promise In the Treatment of Brain Cancers
- ImVisioN Therapeutics Reports Positive Phase I Clinical Results for Treatment of Cat Dander Allergy
March 20, 2009
- Publication Highlights Potential of Santhera's Oral MC4-Receptor Antagonist Program for Treatment of Cancer Cachexia
- Palonosetron Warrants Adequate Caloric Intake In Oncology Patients Receiving High Emetogenic Chemotherapy
- Oncolytics Biotech Inc. Collaborators Update Combination Reolysin and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
- Oncolytics Biotech Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination Reolysin and Paclitaxel/Carboplatin Trial
March 23, 2009
- Neuromed Announces Exalgo (hydromorphone HCl) Extended-Release Tab...
- Advaxis Updates Phase I Trial Survival Data: 23% of Patients Still Surviving after 2+ Years
- Metabasis Therapeutics Announces Positive Results in a Clinical Trial of MB07803 in Patients with Poorly Controlled Type 2 Diabetes
March 24, 2009
- Vical's Allovectin-7 Phase 3 Trial Receives Positive Review From Safety Monitoring Board
- Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
- Endocyte Announces Positive Interim Results from Phase II Clinical Trial of EC145 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
March 25, 2009
- Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
- Orexo announces Phase IIa data on OX914 in rhinitis
- Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
- News Alert: HemCon Announces Improved Results from Live Nail Infection Study
March 26, 2009
- Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
- Celtic Pharma - Successful Outcome of Phase II Trial for Topical Treatment of Onychomycosis
- Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
- Positive Phase 3 uveitis trial results for voclosporin reported by Isotechnika's partner Lux Biosciences
- Reata Completes Financing and Expands Team to Capture Opportunity Created by Encouraging Clinical Data in Chronic Kidney Disease
- Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
- Lux Biosciences Reports Positive Results from LUMINATE Phase 3 Program of LX211 (LUVENIQ) in Uveitis
- Positive Results from Neurotech's NT-501 Phase 2 Dry AMD (Geographic Atrophy) Study Demonstrate Proof of Concept
- RegeneRx Reports Phase II Venous Stasis Trial Results
- Hythiam Announces Results of Two Double-Blind, Placebo-Controlled Studies on Impact of Prometa Treatment Program for Alcohol Dependence
- VGX Pharmaceuticals' Oral Anti-Inflammatory Drug Safe in Phase I Study
- Boston Scientific Announces Schedule For ACC 2009
March 27, 2009
- Affymax Reports Phase 2 Sub-Analysis of Hematide in Hemodialysis Patients
- Dapagliflozin Clinical Trial Results Indicate Improvement In Key Glycemic Measures In Treatment-Naïve Type 2 Diabetes Patients
- Medgenics' Phase I/II Clinical Trial Now Shows Epodure Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
March 30, 2009
- Crestor Reduced Risk of Blood Clots in the Veins
- Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
- Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal for Fabry Disease at ACMG 2009 Annual Meeting
- Abbott's Market-Leading XIENCE V Shows Increasing Clinical Advantages Over TAXUS Express2/TAXUS Liberte Between Two and Three Years
- Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
- Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
- New Data for Abbott's TRILIPIX (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
- Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
- SYNTAX Analysis Finds Treatment With TAXUS Express2 Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
- Celsion Announces Promising ThermoDox Clinical Results in Primary Liver Cancer Were Published in Expert Opinion
- AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
- Data from Gencaro Phase 3 Best Trial Presented at the American College of Cardiology 58(th) Annual Scientific Session
- Gentium Announces Preliminary Results from a Phase 2/3 European Pediatric Prevention Trial for Veno-Occlusive Disease at the European Group for Blood and Marrow Transplantation Annual Meeting
- Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
- Amorcyte Presents Results of Stem Cell Study at ACC on Improved Blood Circulation After Severe Heart Attack
- Pronova BioPharma ASA (NO) - Findings in the OMEGA study presented
- Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
- Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure
- New Lantheus Study Finds Significant Survival Benefit for Critically Ill Patients Undergoing Contrast-Enhanced Echocardiography
- Comparative Analysis of Four Beta Blocker Trials Presented at the American College of Cardiology 58(th) Annual Scientific Session
- Combination Adult Stem Cell Therapy Improves Severe Limb Ischemia
- Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Change of Company Name to Theraclone Sciences, Inc.
- SARcode Announces Results of Phase 1 Trial of SAR 1118 Ophthalmic Solution in Healthy Adult Subjects
- Schering-Plough Announces Results of the Early ACS Trial
- Intensive Lipitor Therapy Provided Sustained Risk Reduction Of Cardiovascular Events In Older Patients With Heart Disease
March 31, 2009
- Karo Bio Reports Positive Results For Kb3305 In Diabetes Patients
- New analyses of phase 3 data for NicOx’ naproxcinod presented at the American College of Cardiology (ACC) Annual Meeting
- Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix (Varenicline) Compared With Placebo
- Plavix Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants
- Zosano Pharma, Inc. to Present Positive Phase 2 Results of Its Transdermal Patch for Osteoporosis
- Novel PET Myocardial Perfusion Imaging Tracer Data Presented
- Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
- New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
- VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
- New Data Presented at ACC.09 Shows Benefit of Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure Patients
